Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Cited by (1,000)

Items 301–400 of 1,000

1. Vitamin K effects in human health: new insights beyond bone and cardiovascular health
   Maria Fusaro, Maurizio Alberto Gallieni, Camillo Porta, Thomas L. Nickolas, Pascale Khairallah · 2019 · Journal of Nephrology
2. Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer
   Shigeki Nanjo, Wei Wu, Niki Karachaliou, Collin Michael Blakely, Junji Suzuki, Yu‐Ting Chou, Siraj Mahamed Ali, Daniel Lucas Kerr, Victor R. Olivas, Jonathan Shue et al. · 2022 · Journal of Clinical Investigation
3. Lineage factors and differentiation states in lung cancer progression
   William K.C. Cheung, Don X. Nguyen · 2015 · Oncogene
4. Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy
   Mai Badarni, Manu Prasad, Noa Balaban, Jonathan Zorea, Ksenia M. Yegodayev, Ben‐Zion Joshua, Anat Bahat Dinur, Reidar A. Grenman, Barak Rotblat, Limor Cohen et al. · 2019 · JCI Insight
5. Epithelial-to-mesenchymal transition: lessons from development, insights into cancer and the potential of EMT-subtype based therapeutic intervention
   Jane Antony, Jean Paul Thiery, Ruby Yun‐Ju Huang · 2019 · Physical Biology
6. JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma
   Bjoern Titz, Anastasia Lomova, Allison Le, Willy Hugo, Xiangju Kong, Johanna ten Hoeve, Michael Friedman, Hubing Shi, Gatien Moriceau, Chunying Song et al. · 2016 · Cell Discovery
7. The Dual Role of TAM Receptors in Autoimmune Diseases and Cancer: An Overview
   Martha Wium, Juliano D. Paccez, Luiz Fernando Zerbini · 2018 · Cells
8. In-Depth Analysis Shows Synergy between Erlotinib and miR-34a
   Jane Y. Zhao, Kevin Kelnar, Andreas G. Bader · 2014 · PLoS ONE
9. Cancer plasticity in therapy resistance: Mechanisms and novel strategies
   Xing Niu, Wenjing Liu, Zhang Yinling, Jing Liu, Jianjun Zhang, Bo Li, Yue Qiu, Peng Zhao, Zhongmiao Wang, Zhe Wang · 2024 · Drug Resistance Updates
10. Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer
    Arjan Gower, Yisong Wang, Giuseppe Giaccone · 2014 · Journal of Molecular Medicine
11. Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways
    Xinyan Wu, Muhammad Saddiq Zahari, Binyun Ma, Ren Liu, Santosh Renuse, Nandini A. Sahasrabuddhe, Lily Chen, Raghothama Chaerkady, Min‐Sik Kim, Jun Zhong et al. · 2015 · Oncotarget
12. Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis
    Tianyao Lei, Tianwei Xu, Niu Zhang, Xiaoteng Zou, Ziyue Kong, Chenchen Wei, Zhaoxia Wang · 2023 · Pharmacological Research
13. Receptor Tyrosine Kinases Fall into Distinct Classes Based on Their Inferred Signaling Networks
    Joel P. Wagner, Alejandro Wolf‐Yadlin, Mark Sevecka, Jennifer K. Grenier, David E. Root, Douglas A. Lauffenburger, Gavin MacBeath · 2013 · Science Signaling
14. Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells
    Sílvia Cufí, Rosa Bonavia, Alejandro Vázquez‐Martín, Bruna Corominas-Faja, Cristina Oliveras‐Ferraros, Elisabet Cuyàs, Begoña Martı́n-Castillo, Enrique Barrajón‐Catalán, Joana Visa, Antonio Segura‐Carretero et al. · 2013 · Food and Chemical Toxicology
15. AXL is an oncotarget in human colorectal cancer
    Erika Martinelli, Giulia Martini, Claudia Cardone, Teresa Troiani, Giuseppina Liguori, Donata Vitagliano, Stefania Napolitano, Floriana Morgillo, Barbara Rinaldi, Rosa Marina Melillo et al. · 2015 · Oncotarget
16. High throughput scaffold-based 3D micro-tumor array for efficient drug screening and chemosensitivity testing
    Xiaojun Yan, Lyu Zhou, Zhaozhao Wu, Xun Wang, Xiuyuan Chen, Fan Yang, Yanan Guo, Min Wu, Yuyang Chen, Wenjing Li et al. · 2018 · Biomaterials
17. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents
    Nellie K. McDaniel, Christopher T. Cummings, Mari Iida, Justus M. Huelse, Hannah E. Pearson, Eleana Vasileiadi, Rebecca E. Parker, Rachel A. Orbuch, Olivia J. Ondracek, Noah B. Welke et al. · 2018 · Molecular Cancer Therapeutics
18. Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer
    Michihiko Kuwano, Kahori Sonoda, Yûichi Murakami, Kosuke Watari, Mayumi Ono · 2016 · Pharmacology & Therapeutics
19. Novel Points of Attack for Targeted Cancer Therapy
    Gro Vatne Røsland, Agnete S. T. Engelsen · 2014 · Basic & Clinical Pharmacology & Toxicology
20. Mechanisms of resistance to EGFR targeted therapies
    Gorjan Hrustanovic, Bianca J. Lee, Trever Grant Bivona · 2013 · Cancer Biology & Therapy
21. Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK -Translocated Lung Cancer Cells
    Tetsuo Tani, Hiroyuki Yasuda, Junko Hamamoto, Aoi Kuroda, Daisuke Arai, Kota Ishioka, Keiko Ohgino, Masayoshi Miyawaki, Ichiro Kawada, Katsuhiko Naoki et al. · 2015 · Molecular Cancer Therapeutics
22. NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors
    Marc McGowan, Lilach Kleinberg, Ann Rita Halvorsen, Åslaug Helland, Odd Terje Brustugun · 2017 · Genes & Cancer
23. Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer
    Josephine Amalia Taverna, Chia‐Nung Hung, Daniel T. DeArmond, Meizhen Chen, Chun-Lin Lin, Paweł A. Osmulski, Maria E. Gaczynska, Chiou‐Miin Wang, Nicholas L. L. Lucio, Chih‐Wei Chou et al. · 2020 · Cancer Research
24. AXL confers cell migration and invasion by hijacking a PEAK1-regulated focal adhesion protein network
    Afnan Abu-Thuraia, Marie-Anne Goyette, Jonathan Boulais, Carine Delliaux, Chloé Apcher, Céline Schott, Rony Chidiac, Halil Bagci, Marie-Pier Thibault, Dominique Davidson et al. · 2020 · Nature Communications
25. Trastuzumab resistance induces EMT to transform HER2+ PTEN− to a triple negative breast cancer that requires unique treatment options
    Joseph Burnett, Hasan Körkaya, Maria Ouzounova, Hui Jiang, Sarah J. Conley, Bryan W. Newman, Lichao Sun, Jamie N. Connarn, Ching‐Shih Chen, Ning Zhang et al. · 2015 · Scientific Reports
26. Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer
    Kyu Sic You, Yong Weon Yi, Jeonghee Cho, Jeong‐Soo Park, Yeon‐Sun Seong · 2021 · Pharmaceuticals
27. Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling
    Andreas N. WICKI, Mario Mandalà, Daniela Massi, Daniela Taverna, Huifang Tang, Brian A. Hemmings, Gongda Xue · 2016 · Physiological Reviews
28. Erlotinib-Cisplatin Combination Inhibits Growth and Angiogenesis through c-MYC and HIF-1α in EGFR-Mutated Lung Cancer In Vitro and In Vivo
    Jasmine G. Lee, Reen Wu · 2015 · Neoplasia
29. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials
    Saurabh Chhabra, Natalie S. Callander, Nicole Watts, Luciano J. Costa, Bicky Thapa, Jonathan L. Kaufman, Jacob P. Laubach, Douglas Weston Sborov, Brandi Reeves, Cesar Rodriguez et al. · 2022 · Transplantation and Cellular Therapy
30. Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib
    Alfredo Tartarone, Chiara Lazzari, Rosa Lerose, Vincenza Conteduca, Giuseppina Improta, Angela Zupa, Alessandra Bulotta, Michele Aieta, Vanesa Gregorc · 2013 · Lung Cancer
31. Axl Receptor Blockade Ameliorates Pulmonary Pathology Resulting from Primary Viral Infection and Viral Exacerbation of Asthma
    Takehiko Shibata, David M. Habiel, Ana Lúcia Coelho, Steven L. Kunkel, Nicholas W. Lukacs, Cory M. Hogaboam · 2014 · The Journal of Immunology
32. Crosstalk with cancer-associated fibroblasts induces resistance of non-small cell lung cancer cells to epidermal growth factor receptor tyrosine kinase inhibition
    Chung Choe, Yong-Sung Shin, So‐Jung Choi, Jinseon Lee, So Young Kim, Yong Beom Cho, Jhingook Kim, Changhoon Kim · 2015 · OncoTargets and Therapy
33. IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib
    Romaine Ingrid Fernando, Duane H. Hamilton, Charli L. Dominguez, Justin M. David, Kristen K. McCampbell, Claudia Palena · 2016 · Oncotarget
34. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors
    John Bisi, Jessica A. Sorrentino, Jamie L. Jordan, David D. Darr, Patrick J. Roberts, Francis X. Tavares, Jay C. Strum · 2017 · Oncotarget
35. Resistance to molecularly targeted therapy in non-small-cell lung cancer
    Tetsuhiko Asao, Fumiyuki Takahashi, Kazuhisa Takahashi · 2018 · Respiratory Investigation
36. Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor
    Donatella Romaniello, Ilaria Marrocco, Nishanth Belugali Nataraj, Irene Ferrer, Diana Drago Garcia, Itay Vaknin, Roni Oren, Moshit Lindzen, Soma Ghosh, Matthew Kreitman et al. · 2020 · Cancers
37. AXL Inhibitors: Status of Clinical Development
    Sheena Bhalla, David E. Gerber · 2023 · Current Oncology Reports
38. Heterogeneity of Pancreatic Cancer Metastases in a Single Patient Revealed by Quantitative Proteomics
    Min‐Sik Kim, Yi Zhong, Shinichi Yachida, N.V. Rajeshkumar, Melissa L. Abel, Arivusudar Marimuthu, Keshav Shree Mudgal, Ralph H. Hruban, Justin Poling, Jeffrey W Tyner et al. · 2014 · Molecular & Cellular Proteomics
39. 4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors
    Li Tan, Zhang Zhang, Donglin Gao, Jinfeng Luo, Zhengchao Tu, Zhengqiu Li, Lijie Peng, Xiaomei Ren, Ke Ding · 2016 · Journal of Medicinal Chemistry
40. Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells
    Yaqiong Tian, Zengli Zhang, Liyun Miao, Zhimin Yang, Jie Yang, Yinhua Wang, Danwen Qian, Hourong Cai, Yongsheng Wang · 2016 · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
41. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition
    Wei Lou, Yan Chen, Keying Zhu, Huizi Deng, Tianhao Wu, Jun Wang · 2017 · Biological and Pharmaceutical Bulletin
42. A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)
    Ziad Abuhelwa, Abdurahman Alloghbi, Misako Nagasaka · 2022 · Cancer Treatment Reviews
43. Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer
    Yi‐Nan Liu, Meng‐Feng Tsai, Shang‐Gin Wu, Tzu‐Hua Chang, Tzu-Hsiu Tsai, Chien‐Hung Gow, Yih‐Leong Chang, Jin‐Yuan Shih · 2019 · International Journal of Cancer
44. Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer
    Zixi Wang, Yurou Xing, Bingjie Li, Xiaoyu Li, Bin Liu, Yongsheng Wang · 2022 · Molecular Biomedicine
45. Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo
    Julia Onken, Robert Torka, Sören Korsing, Josefine Radke, Irina Krementeskaia, Melina Nieminen-Kelhä, Xi Bai, Axel Ullrich, Frank L. Heppner, Peter Vajkoczy · 2016 · Oncotarget
46. RAS–MAPK Reactivation Facilitates Acquired Resistance in FGFR1 -Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR–MEK Blockade
    Bruno Bockorny, Maria Rusan, Wankun Chen, Rachel G. Liao, Yvonne Y. Li, Federica Piccioni, Jun Wang, Li Tan, Aaron R. Thorner, Tianxia Li et al. · 2018 · Molecular Cancer Therapeutics
47. CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC
    Jeffrey H. Becker, Yandi Gao, Margaret Soucheray, Inés Pulido, Eiki Kikuchi, María L. Rodríguez, Rutu Gandhi, Aránzazu Lafuente-Sanchis, Miguel Aupí, Javier Alcácer Fernández-Coronado et al. · 2019 · Cancer Research
48. Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer.
    Peter Stephen Savas, Brett G.M. Hughes, Benjamin Solomon · 2013 · Europe PMC (PubMed Central)
49. Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer
    Louise A. Koopman, Mikkel G. Terp, Gijs G. Zom, Maarten L. Janmaat, Kirstine Jacobsen, Elke Gresnigt-Van den Heuvel, Marcel Brandhorst, Ulf Forssmann, Freddy De Bree, Nora Pencheva et al. · 2019 · JCI Insight
50. Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells
    Valentina M. Russo, Alessia Paciocco, Alessandra Affinito, Giuseppina Roscigno, Danilo Fiore, Francesco Palma, Marco Galasso, Stefano Volinia, Alfonso Fiorelli, Carla Lucia Esposito et al. · 2018 · Molecular Therapy — Nucleic Acids
51. Genome-wide CRISPR screening reveals genetic modifiers of mutant EGFR dependence in human NSCLC
    Zeng, Hao, Castillo-Cabrera, Johnny, Manser, Mika, Lu, Bo, Yang, Zinger, Strande, Vaik, Begue, Damien, Zamponi, Raffaella, Qiu, Shumei, Sigoillot, Frederic et al. · 2019 · eLife
52. Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
    Anna Adam‐Artigues, Enrique Javier Arenas, A. Martínez, Fara Brasó‐Maristany, Raimundo Cervera, Eduardo Tormo, Cristina Hernándo, María Teresa Martínez, Juan Antonio Carbonell‐Asins, Soraya Simón et al. · 2022 · Science Advances
53. The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies
    Carmelo Laface, Felicia Maria Maselli, Anna Natalizia Santoro, Maria Laura Iaia, Francesca Ambrogio, Marigia Laterza, Chiara Guarini, Pierluigi De Santis, Martina Perrone, Palma Fedele · 2023 · Pharmaceutics
54. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner
    Robin E. Frink, Michael Peyton, Joan H. Schiller, Adi F. Gazdar, Jerry W. Shay, John Dorrance Minna · 2016 · Oncotarget
55. Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma
    Yoon Soo Chang, Chang‐Min Choi, Jae Cheol Lee · 2016 · Tuberculosis & respiratory diseases
56. MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR -mutant Lung Cancer
    Shigeki Nanjo, Sachiko Arai, Wei Wang, Shinji Takeuchi, Tadaaki Yamada, Akito Hata, Nobuyuki Katakami, Yasunori Okada, Seiji Yano · 2017 · Molecular Cancer Therapeutics
57. Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
    Sangyong Jung, Dong Ha Kim, Yun Jung Choi, Seon Ye Kim, Hyojeong Park, Hyeonjeong Lee, Chang‐Min Choi, Young Hoon Sung, Jae Cheol Lee, Jin Kyung Rho · 2021 · Scientific Reports
58. The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges
    Yun Beom Sang, Joo-Hang Kim, Chang-Gon Kim, Min Hee Hong, Hye Ryun Kim, Byoung Chul Cho, Sun Min Lim · 2022 · Frontiers in Oncology
59. Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update
    Aarif Ahsan · 2015 · Advances in experimental medicine and biology
60. Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity
    Stanley Gititu Kimani, Sushil Kumar, Nitu Bansal, Kamalendra Singh, Vladyslav V. Kholodovych, Thomas W. Comollo, Youyi Peng, Sergei V. Kotenko, Stefan G. Sarafianos, Joseph R. Bertino et al. · 2017 · Scientific Reports
61. Signaling pathways and mesenchymal transition in pediatric high-grade glioma
    Michaël Hananja Meel, Sophie A. Schaper, Gertjan J.L. Kaspers, Esther Hulleman · 2017 · Cellular and Molecular Life Sciences
62. Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer
    Dinoop Ravindran Menon, Heinz Hammerlindl, Joachim Torrano, Helmut Schaider, Mayumi Fujita · 2020 · Theranostics
63. Efferocytosis: An accomplice of cancer immune escape
    Hui Qiu, Zhiying Shao, Xin Wen, Zhengyang Liu, Ziqin Chen, Debao Qu, Xin Ding, Longzhen Zhang · 2023 · Biomedicine & Pharmacotherapy
64. Kinome-wide shRNA Screen Identifies the Receptor Tyrosine Kinase AXL as a Key Regulator for Mesenchymal Glioblastoma Stem-like Cells
    Peng Cheng, Emma S. Phillips, Sung-Hak Kim, David Taylor, Thomas Hielscher, Laura Puccio, Anita B. Hjelmeland, Peter Lichter, Ichiro Nakano, Violaine Goidts · 2015 · Stem Cell Reports
65. Molecular Mechanism of 17-Allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL Receptor Tyrosine Kinase Degradation
    Gnana Prakasam Krishnamoorthy, Teresa Guida, Luigi Alfano, Elvira Avilla, Massimo Mattia Santoro, Francesca Carlomagno, Rosa Marina Melillo · 2013 · Journal of Biological Chemistry
66. Small Molecule Inhibition of MERTK Is Efficacious in Non–Small Cell Lung Cancer Models Independent of Driver Oncogene Status
    Christopher T. Cummings, Weihe Zhang, Kurtis D. Davies, Gregory D. Kirkpatrick, Dehui� Zhang, Deborah DeRyckere, Xiaodong Wang, Stephen V. Frye, Henry Shelton Earp, Douglas K. Graham · 2015 · Molecular Cancer Therapeutics
67. Genome-Scale Signatures of Gene Interaction from Compound Screens Predict Clinical Efficacy of Targeted Cancer Therapies
    Peng Jiang, Winston Lee, Xujuan Li, Carl Johnson, Jun S. Liu, Myles A Brown, Jon Christopher Aster, X. Shirley Liu · 2018 · Cell Systems
68. Engineering Axl specific CAR and SynNotch receptor for cancer therapy
    Jang Hwan Cho, Atsushi Okuma, Dalal Al-Rubaye, Ejaj Intisar, Richard Paul Junghans, Wilson W. Wong · 2018 · Scientific Reports
69. YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics
    Pang‐Dian Fan, Giuseppe Narzisi, Anitha Devi Jayaprakash, Elisa Venturini, Nicolas Robine, Peter Smibert, Søren Germer, Helena Alexandra Yu, Emmet Jordan, Paul K. Paik et al. · 2018 · Proceedings of the National Academy of Sciences
70. The insulin‐like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild‐type epidermal growth factor receptor
    Kenichi Suda, Hiroshi Mizuuchi, Katsuaki Sato, Toshiki Takemoto, Takuya Iwasaki, Tetsuya Mitsudomi · 2014 · International Journal of Cancer
71. Cancer chemoresistance and its mechanisms: Associated molecular factors and its regulatory role
    Sandra Kannampuzha, Abilash Valsala Gopalakrishnan · 2023 · Medical Oncology
72. Personalized prediction of EGFR mutation-induced drug resistance in lung cancer
    Debby D. Wang, Weiqiang Zhou, Hong Yan, Maria Pik Wong, Victor Ho-Fun Lee · 2013 · Scientific Reports
73. Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non–Small Cell Lung Cancer
    Alexandra B. Lantermann, Dongshu Chen, Kaitlin McCutcheon, Greg Hoffman, Elizabeth Frias, David A. Ruddy, Daniel P. Rakiec, Joshua M. Korn, Gregory McAllister, Frank P. Stegmeier et al. · 2015 · Cancer Research
74. Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial–mesenchymal transition
    Steven Hsesheng Lin, Jing Wang, Pierre Saintigny, Chia-Chin Wu, Uma P. Giri, Jing Zhang, Toshi Menju, Lixia Diao, Lauren A. Byers, John N. Weinstein et al. · 2014 · BMC Genomics
75. A TAZ-AXL-ABL2 Feed-Forward Signaling Axis Promotes Lung Adenocarcinoma Brain Metastasis
    Jacob P. Hoj, Benjamin Mayro, Ann Marie Pendergast · 2019 · Cell Reports
76. CDK4/6 inhibitor palbociclib overcomes acquired resistance to third‐generation EGFR inhibitor osimertinib in non‐small cell lung cancer ( NSCLC )
    Qiong Qin, Xiaoqing Li, Xingmei Liang, Lili Zeng, Jing Wang, Linlin Sun, Diansheng Zhong · 2020 · Thoracic Cancer
77. Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients
    Aliki Ntzifa, Areti D. Strati, Galatea Kallergi, Athanasios Panayotis Kotsakis, Vassilis Georgoulias, Evi S. Lianidou · 2021 · Scientific Reports
78. Cross-talk between SOX2 and TGFβ Signaling Regulates EGFR–TKI Tolerance and Lung Cancer Dissemination
    Ming-Han Kuo, An-Chun Lee, Shih-Hsin Hsiao, Sey‐En Lin, Yu-Fan Chiu, Li-Hao Yang, Chia-Cherng Yu, Shih‐Hwa Chiou, Hsien‐Neng Huang, Jen‐Chung Ko et al. · 2020 · Cancer Research
79. Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies
    Marta Tapia, Cristina Hernándo, María Teresa Martínez, Octavio Burgués, Cristina Tebar, Ana Lameirinhas, Anna Ágreda‐Roca, Sandra Torres‐Ruiz, Iris Garrido‐Cano, Ana M. Lluch et al. · 2023 · Cancers
80. Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer
    Wei Jiang, Meiju Ji · 2019 · Seminars in Cancer Biology
81. AXL Inhibition Induces DNA Damage and Replication Stress in Non–Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors
    Kavya Ramkumar, Catherine Allison Stewart, Kasey R. Cargill, Carminia Maria Della Corte, Qi Wang, Li Shen, Lixia Diao, Robert J. Cardnell, David H. Peng, B. Leticia Rodriguez et al. · 2020 · Molecular Cancer Research
82. Combined Inhibitions of Glycolysis and AKT/autophagy Can Overcome Resistance to EGFR-targeted Therapy of Lung Cancer
    Mingtong Ye, Sufan Wang, Ting Wan, Rui Jiang, Yun Qiu, Lei Pei, Nengzhi Pang, Yuanling Huang, Yu‐Feng Huang, Zhenfeng Zhang et al. · 2017 · Journal of Cancer
83. MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer
    Dan Yan, Justus M. Huelse, Dmitri Kireev, Zikang Tan, Luxiao Chen, Subir Goyal, Xiaodong Wang, Stephen V. Frye, Madhusmita Behera, Frank Schneider et al. · 2022 · Journal of Clinical Investigation
84. The AXL Receptor Is a Sensor of Ligand Spatial Heterogeneity
    Aaron S. Meyer, Annelien J.M. Zweemer, Douglas A. Lauffenburger · 2015 · Cell Systems
85. Cisplatin influences acquisition of resistance to molecular‐targeted agents through epithelial–mesenchymal transition‐like changes
    Maki Kurokawa, Nobuyuki Ise, Kazuya Omi, Katsutoshi Goishi, Shigeki Higashiyama · 2013 · Cancer Science
86. Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib
    Wei Xu, Yunyan Wei, Shuangshuang Wu, Yun Wang, Zhen Wang, Yu Sun, Steven Yan Cheng, Jianqing Wu · 2015 · Cell & Bioscience
87. Diet-derived 25-hydroxyvitamin D3 activates vitamin D receptor target gene expression and suppressesEGFRmutant non-small cell lung cancer growthin vitroandin vivo
    Alissa R. Verone-Boyle, Suzanne F. Shoemaker, Kristopher M. Attwood, Carl D. Morrison, Andrew J. Makowski, Sebastiano Battaglia, Pamela A. Hershberger · 2015 · Oncotarget
88. Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario
    Alfredo Addeo, Fabrizio Tabbò, Tim Robinson, Lucio Buffoni, Silvia Novello · 2017 · Critical Reviews in Oncology/Hematology
89. Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer
    Jeanne M. Quinn, Molly M. Greenwade, Marguerite L. Palisoul, Gregory Opara, Katina Massad, Lei Guo, Peinan Zhao, Hollie Beck-Noia, Ian S. Hagemann, Andrea R. Hagemann et al. · 2018 · Molecular Cancer Therapeutics
90. Lipid transporter Spns2 promotes microglia pro‐inflammatory activation in response to amyloid‐beta peptide
    Liansheng Zhong, Xue Jiang, Zhihui Zhu, Haiyan Qin, Michael B. Dinkins, Ji‐Na Kong, Silvia Leanhart, Rebecca Wang, Ahmed M. Elsherbini, Erhard Bieberich et al. · 2018 · Glia
91. AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer
    Nellie K. McDaniel, Mari Iida, Kwangok P. Nickel, Colin A. Longhurst, Samantha R. Fischbach, Tamara S. Rodems, Carlene A. Kranjac, Amber Y. Bo, Qianyun Luo, Meghan M. Gallagher et al. · 2020 · Clinical Cancer Research
92. Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities
    Pritam Maity, Joydeep Chatterjee, Kiran T. Patil, Sahil Arora, Madhurendra Kumar Katiyar, Manvendra Kumar, Amirreza Samarbakhsh, Gaurav Joshi, Priyadeep Bhutani, Manoj Chugh et al. · 2023 · Journal of Medicinal Chemistry
93. Curcumin-induced downregulation of Axl receptor tyrosine kinase inhibits cell proliferation and circumvents chemoresistance in non-small lung cancer cells
    KYUNG-CHAN KIM, Suk‐Hwan Baek, ChuHee Lee · 2015 · International Journal of Oncology
94. An activation of LC3A ‐mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma
    Kaito Nihira, Yasuhiro Miki, Shinya Iida, Sodai Narumi, Katsuhiko Ono, Erina Iwabuchi, Kazue Ise, Kazushige Mori, Mikiyoshi Saito, Masahito Ebina et al. · 2014 · The Journal of Pathology
95. PHD3 Controls Lung Cancer Metastasis and Resistance to EGFR Inhibitors through TGFα
    Higinio Dopeso, Huike Jiao, Ángel M. Cuesta, Anne‐Theres Henze, Liane Jurida, Michael Kracht, Amparo Acker‐Palmer, Boyan K. Garvalov, Till Acker · 2018 · Cancer Research
96. Chemical Proteomics Uncovers EPHA2 as a Mechanism of Acquired Resistance to Small Molecule EGFR Kinase Inhibition
    Heiner Koch, M. Estela del Castillo Busto, Karl Kramer, Guillaume Médard, Bernhard Küster · 2015 · Journal of Proteome Research
97. Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)
    Carles Codony, Jordi Codony‐Servat, Niki Karachaliou, Miguel Ángel Molina‐Vila, Imane CHAIB-OUKADOUR, José Luis Ramírez, María de los Llanos Gil, Flavio Solca, Trever Grant Bivona, Rafael Rosell · 2017 · Oncotarget
98. Integrated single-cell and bulk gene expression and ATAC-seq reveals heterogeneity and early changes in pathways associated with resistance to cetuximab in HNSCC-sensitive cell lines
    Luciane Tsukamoto Kagohara, Fernando Tadeu Zamunér, Emily F. Davis-Marcisak, Gaurav Sharma, Michael Considine, Jawara Allen, Srinivasan Yegnasubramanian, Daria A. Gaykalova, Elana Judith Fertig · 2020 · British Journal of Cancer
99. Exosome‐transmitted linc00852 associated with receptor tyrosine kinase AXL dysregulates the proliferation and invasion of osteosarcoma
    Qiming Li, Xuedi Wang, Nian Jiang, Xianbiao Xie, Ni Liu, JunFeng Liu, Jingnan Shen, Tingsheng Peng · 2020 · Cancer Medicine
100. Osimertinib versus osimertinib plus chemotherapy for non–small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial
     Kentaro Tanaka, Hajime Asahina, Junji Kishimoto, Yoshihiro Miyata, Takahiro Uchida, Kana Watanabe, Kosuke Hamai, Taishi Harada, Yukari Tsubata, Shunichi Sugawara et al. · 2021 · European Journal of Cancer